Developing Novel Carriers to Deliver Targeted Immunotoxins for the Treatment of Primary and Metastatic Non-Small Cell Lung Cancer

Abstract

Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer which is a leading cause of cancer death. Most patients (>80%) present with advanced NSCLC when curative surgery is no longer an option. Other conventional therapies, such as chemotherapy, radiotherapy and existing molecular targeted therapy have neither significantly extended the life span of most patients, nor improved their quality of life. This is not only because of the large tumor load in the advanced stage of NSCLC but its metastasis. This project devises a novel approach to shield the “magic bullet” and help it locate and kill targeted cancer cells.